Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage III Pancreatic Cancer AJCC v6 and v7: early-phase trial registry
A small indexed set (7 trials) with no open enrollment listed right now.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · none currently recruiting · #2,497 of 28,707 conditions by registered trial count
Stage III Pancreatic Cancer AJCC v6 and v7: 7 US clinical trials tracked, none currently recruiting.
Stage III Pancreatic Cancer AJCC v6 and v7 is the subject of 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition stage-iii-pancreatic-cancer-ajcc-v6-and-v7
OPEN 0 | RECR 0% | LATE 0 | EARLY 7 | RANK #2497 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Stage III Pancreatic Cancer AJCC v6 and v7 has no open enrollment in this registry pull (7 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage III Pancreatic Cancer AJCC v6 and v7 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage III Pancreatic Cancer AJCC v6 and v7 is recruiting below its size-band peers.
0 of 7 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage III Pancreatic Cancer AJCC v6 and v7 research.
National Cancer Institute (NCI) accounts for 4 of 7 trials (57.1%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Stage III Pancreatic Cancer AJCC v6 and v7 trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.
-
Stage III Pancreatic Cancer AJCC v6 and v7 research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
7 total, page 1 of 1
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
NCT02498613
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
University of Nebraska
NCT03073785
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
NCT02336087
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01660971
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00669734
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
University of Washington
NCT02451553
3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00288093
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage III Pancreatic Cancer AJCC v6 and v7 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage III Pancreatic Cancer AJCC v6 and v7 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage III Pancreatic Cancer AJCC v6 and v7 page
7 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Stage III Pancreatic Cancer AJCC v6 and v7 trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Stage III Pancreatic Cancer AJCC v6 and v7 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Pancreatic Cancer AJCC v6 and v7 condition card totals 7 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.